<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg"/>
                                    
                                    <figcaption>Both companies will jointly oversee early-stage development of the antibody candidates. Credit: SmartPhotoLab / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s newly identified de novo amyloid beta antibody programme aimed at treating Alzheimer’s disease.</p>



<p>The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Eli Lilly and Co's Remternetug </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: SanBio Co Ltd's SB-623 </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Both companies will jointly oversee early-stage development of the antibody candidates. Following the initial stages, Novartis will assume responsibility for all further product development and commercialisation worldwide.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Under the agreed terms, SciNeuro will receive an upfront payment of $165m. The company may also receive research funding, along with up to $1.5bn in potential development, regulatory and commercial milestones. Tiered royalties will also be available.</p>



<p>Completion of the transaction is anticipated in the first half of 2026, subject to the end or waiver of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period and fulfilment of customary closing conditions.</p>



<p>SciNeuro founder and CEO Min Li said: “The anti-amyloid programme represents one of SciNeuro’s key strategic R&amp;D priorities to target neurodegenerative disease. We are thrilled to collaborate with Novartis to continue its development, given its preeminent capabilities and commitment to next-generation therapies for neurodegenerative diseases.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>“This collaboration delivers an optimal synergy, combining our expertise in disease biology and early development with Novartis’ global leadership in clinical development and commercialisation.”</p>



<p>Novartis biomedical research neuroscience global head Robert Baloh said: “There is a pressing need for new and differentiated therapeutics to help alleviate suffering in devastating neurological diseases such as Alzheimer’s disease.</p><div id="slot-two"></div>



<p>“We are happy to be collaborating with SciNeuro, an organisation which has proprietary technology aiming to safely and effectively target amyloid beta and which shares our sense of urgency and commitment to this disease area.”</p>



<p>In October 2025, Novartis signed an agreement to acquire all outstanding shares of US-based Avidity Biosciences for $12bn in cash on a fully diluted basis. </p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

<p>SciNeuro Pharmaceuticals has entered a global licensing agreement with Novartis to develop an amyloid beta antibody for Alzheimer's disease. The collaboration will focus on early-stage development, with Novartis taking over later stages and commercialization. SciNeuro will receive $165 million upfront, potential research funding, and up to $1.5 billion in milestone payments. The deal is expected to close in the first half of 2026, pending regulatory approvals. Both companies aim to leverage their expertise to address the urgent need for new Alzheimer's therapies.</p>

SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody